Statement on management of lung disease associated with alpha-1 antitrypsin deficiency

Chairs: Robert Stockley & Marc Miravitlles

Although Alpha-1-Antitrypsin Deficiency (AATD) is recognised as a genetic predisposition to emphysema it has been over 10 years since the writing of the last Guidelines. Since then a large descriptive literature and a small number of therapeutic clinical trials have been undertaken. The project of this Task Force is to bring together European expertise in the diagnosis, interpretation of results, patient assessment and management of the disease. This will provide state of the art information for healthcare workers and patients.